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Abstract
Background: Hip dysplasia and osteoarthritis continue to be prevalent problems in veterinary and human
medicine. Canine hip dysplasia is particularly problematic as it massively affects several large-sized breeds and can
cause a severe impairment of the quality of life. In Finland, the complex condition is categorized to five classes
from normal to severe dysplasia, but the categorization includes several sub-traits: congruity of the joint, Norberg
angle, subluxation degree of the joint, shape and depth of the acetabulum, and osteoarthritis. Hip dysplasia and
osteoarthritis have been proposed to have separate genetic etiologies.
Results: Using Fédération Cynologique Internationale -standardized ventrodorsal radiographs, German shepherds
were rigorously phenotyped for osteoarthritis, and for joint incongruity by Norberg angle and femoral head center
position in relation to dorsal acetabular edge. The affected dogs were categorized into mild, moderate and severe
dysplastic phenotypes using official hip scores. Three different genome-wide significant loci were uncovered. The
strongest candidate genes for hip joint incongruity were noggin (NOG), a bone and joint developmental gene on
chromosome 9, and nanos C2HC-type zinc finger 1 (NANOS1), a regulator of matrix metalloproteinase 14 (MMP14)
on chromosome 28. Osteoarthritis mapped to a long intergenic region on chromosome 1, between genes
encoding for NADPH oxidase 3 (NOX3), an intriguing candidate for articular cartilage degradation, and AT-rich
interactive domain 1B (ARID1B) that has been previously linked to joint laxity.
Conclusions: Our findings highlight the complexity of canine hip dysplasia phenotypes. In particular, the results of
this study point to the potential involvement of specific and partially distinct loci and genes or pathways in the
development of incongruity, mild dysplasia, moderate-to-severe dysplasia and osteoarthritis of canine hip joints.
Further studies should unravel the unique and common mechanisms for the various sub-traits.
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Background
Canine hip dysplasia (CHD) is a common multifactorial
hereditary disorder that has perplexed dog owners,
breeders as well as veterinarians and researchers for de-
cades. A standardized system for CHD grading has been
developed in the countries that belong to the Fédération
Cynologique Internationale (FCI). The FCI score is di-
vided into five categories alphabetically: A to E, where A
is normal and E is severe CHD. In Finland, the FCI score
is defined separately for both hip joints, hence the for-
mat is given as: left hip score / right hip score. The FCI
score is determined from different ‘sub-traits’ of the hip:
congruency of the joint, Norberg angle (NoA), sublux-
ation degree of the joint, shape and depth of the acet-
abulum, and whether there are any visible signs of
osteoarthritis (OA) in the joint or not. FCI has derived
the grading rules, from which the Finnish Kennel Club
(FKC) has defined their guidelines for radiographing and
scoring hip dysplasia [1]. The above-mentioned sub-
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traits are not recorded for later use, only the hip score is
stored in the FKC database.
As the FCI or any other combinatory score does not
accurately correlate with the various CHD sub-traits,
these have to be studied separately. NoA and femoral
head center position in relation to dorsal acetabular edge
(FHCDAE) reflect the incongruity of the hip joint, which
impacts the development of CHD [2]. Hip joint laxity is
a major contributor to the development of OA. How-
ever, OA is suggested to develop due to many simultan-
eous pathologies, which influence the central structures
of the joint [3]. OA may have a distinct genetic back-
ground in relation to the other hip sub-traits [4–6].
The current consensus is that CHD is polygenic, and
genetic contribution to the phenotype can vary from small
to moderate [7–14]. Variation between breeds is evident
from several studies [5, 7, 9, 10, 14–16]. Some breeds are
more susceptible to the disorder than others. Labrador Re-
trievers [7, 10, 17], Bernese Mountain dogs [9], Golden
Retrievers [18], and German Shepherds [4, 14, 16] have
been under special interest in studies of CHD, and several
genetic associations with different hip phenotypes have
been reported in these breeds. Different breeding strat-
egies have been proposed to improve hip health; estimated
breeding values are generally considered the most efficient
approach [4, 19–22]. Also, newer methods like genomic
selection might bring a long awaited solution in the fight
against this disorder [17, 23, 24].
To better understand the genetic etiology of CHD re-
lated phenotypes, we have carried out here a successful
genome-wide association study (GWAS) in a cohort of
over 750 well-phenotyped German Shepherds to map loci
for CHD and related sub-traits. We report three loci with
genome-wide significance and two suggestive loci for dif-
ferent traits with physiologically relevant candidate genes.
Results
The joint incongruity, measured as FHCDAE and NoA,
map to chromosomes 9, 25 and 28
Incongruity of the hip joint contributes to CHD. There-
fore, we carried out two different association analyses on
incongruity related traits, FHCDAE and NoA, which
were assessed by two different veterinarians in our
group. Both traits were measured for right and left hip,
but we used only the worst measure in the analysis.
NoA showed significant inter-observer variation in a lin-
ear regression model (P = 0.028, Additional file 1), which
is consistent with earlier findings [25, 26]. Therefore, the
evaluator was included as a covariate in the association
analysis of NoA. For FHCDAE the inter-observer vari-
ation was non-significant. The association results for
FHCDAE and NoA indicated overlapping loci, which is
not surprising as these measurements were highly nega-
tively correlated in the study cohort (Pearson’s r = −
0.94, Fig. 1). However, all the observed associations
throughout the loci were stronger for FHCDAE than for
NoA (Table 1).
On chromosome 9, two SNPs demonstrated associ-
ation with FHCDAE (Fig. 2). One of these SNPs passed
the threshold for significance with independent tests
(BICF2G630834826 with a P-value of 1.57 × 10–6, Table
1). BICF2G630834826 and BICF2P742007 are located ~
22 kb downstream and ~ 67 kb upstream of NOG encod-
ing noggin (Additional file 2), and they are in high link-
age disequilibrium (LD) measured as the squared value
(r2) of Pearson’s correlation coefficient between pairs of
SNPs (r2 = 0.84, Additional file 3). These two SNPs also
associated with NoA but the association was stronger
for FHCDAE. The third SNP on chromosome 9, which
was observed only for NoA (BICF2G630837307) and
was not genome-wide significant, lies ~ 64 kb upstream
of LIM homeobox 1 (LHX1) (Additional file 2).
Other loci with at least a suggestive association with the
incongruity traits were on chromosomes 25 and 28 (Table
1, Fig. 2). On chromosome 25, BICF2G630468961 show-
ing suggestive association with NoA was intronic to solute
carrier family 7 member 1 (SLC7A1) (Additional file 2).
On chromosome 28, SNPs BICF2P1046032 (in high LD
with BICF2P895332; r2 = 0.96, Additional file 3) demon-
strated significant association with FHCDAE (Table 1).
These SNPs located between CDK2 associated cullin do-
main 1 (CACUL1) (~ 18 and 30 kb upstream, respectively)
and nanos C2HC-type zinc finger 1 (NANOS1) (~ 163 and
174 kb upstream, respectively) (Additional file 2).
OA maps to chromosome 1
We studied OA as a separate disorder. Two veterinar-
ians in our group evaluated the radiographs of individual
dogs for evidence of OA (see methods). The dogs exhib-
ited either no radiographic evidence of OA (controls) or
had mild, moderate or severe signs of OA (cases). A
case-control association analysis, where all controls
(N = 492) were compared with all cases regardless of the
severity of OA (N = 163), revealed a genome-wide sig-
nificant locus on chromosome 1 (Fig. 3). The SNP with
the strongest association (BICF2P468585) had a P-value
of 2.86 × 10–7 (Table 2). The second-best SNP
(BICF2P357728) reached a P-value of 8.93 × 10–7 (Table
2). Both SNPs passed the threshold for genome-wide sig-
nificance based on the estimated number of independent
tests determined with simpleM (1.82 × 10–6).
The two genome-wide significant SNPs, as well as four
out of the six SNPs showing suggestive association with
OA on this chromosome, located between NADPH oxi-
dase 3 (NOX3) (except BICF2S23248027, which lies
within the ninth intron of NOX3) and AT-rich inter-
action domain 1B (ARID1B) (Table 2, Additional file 2).
The top SNPs BICF2P468585 and BICF2P357728 were
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observed to be in high LD (r2 = 0.85, Additional file 3).
Otherwise, moderate to perfect LD (r2 = 0.63–1.00) was
observed between these six SNPs, even though the re-
gion they covered was over 1.1Mb long (Additional file
3). Thus, we concluded that these SNPs probably repre-
sent just one locus that associates with the disorder.
SNPs BICF2S23216908 and BICF2S2305568 (Table 2)
are in perfect LD (r2 = 1.00, Additional file 3). Although
they are ~ 1.7Mb away from the other SNPs that associ-
ated with OA on this chromosome, we observed some
LD between these two loci (r2 = 0.50–0.61, Additional
file 3). BICF2S23216908 located within the first intron of
Transmembrane protein 181 (TMEM181) and
BICF2S2305568 within the first intron of Dynein light
chain Tctex-type 1 (DYNLT1).
We also observed suggestive associations for chromosome
9 and 25 for OA. On chromosome 9, BICF2G630837240
locates ~ 101 kb downstream from MRM1 encoding Mito-
chondrial RRNA Methyltransferase 1 and ~ 178 kb
upstream from LHX1 (Table 2, Additional file 2).
Fig. 1 Correlation plot of NoA and FHCDAE. NoA is on the Y-axis and FHCDAE on the X-axis. Above the correlation plot is the distribution of
FHCDAE measurements in the cohort. A respective distribution of the NoA measurements is on the right side of the correlation plot. Pearson’s
r = − 0.94 and P-value = 1.8 × 10–297
Table 1 Top SNPs from the GWAS on FHCDAE and NoA
Trait Chr Locus Alleles N per SNP SNP(s) P-value from FASTA(f), corrected with the
inflation factor lambda (λFHCDAE = 1.000, λNoA = 1.003)
FHCDAE 9 31,477,907
31,387,114
G/A
A/G
642
642
BICF2G630834826
BICF2P742007
1.57 × 10–6
2.13 × 10–6
28 29,111,565
29,122,985
A/C
G/A
627
643
BICF2P1046032
BICF2P895332
1.62 × 10–6
2.86 × 10–6
NoA 9 31,477,907
31,387,114
36,694,174
G/A
A/G
A/G
642
642
640
BICF2G630834826
BICF2P742007
BICF2G630837307
2.22 × 10–6
5.26 × 10–6
9.78 × 10–6
25 10,301,514 A/C 640 BICF2G630468961 9.66 × 10–6
Single-nucleotide polymorphisms (SNPs) with probability values (P-values) < 1.0 × 10–5 are listed. SNPs and the corresponding P-values are in bold font, if the P-
value passed the threshold for genome-wide significance (1.82 × 10–6) determined with the estimated number of independent tests from SimpleM (see methods).
(f)Family-based score test for association (FASTA). Chr = chromosome. N refers to the number dogs in analysis after exclusion of dogs by FASTA because they lack
either the phenotype or a covariate. Covariates for NoA: age at radiographing, genetic cluster, genotyping batch, evaluator. Covariates for FHCDAE: age at
radiographing, genetic cluster, and genotyping batch. See also Additional file 1
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BICF2G630468961 on chromosome 25 is located within the
second intron of SLC7A1 (Table 2 Additional file 2).
Different genetic etiology of mild and moderate-to-severe
CHD
To identify loci for CHD according to the FCI hip
scores, we carried out three sets of case-control associ-
ation analyses. In the first case-control analysis, the con-
trols had a bilateral FCI hip score A and cases B/C, C/B
or bilateral FCI score C or worse (Ncases = 339, Ncontrols =
354). In the second analysis, the same controls were
used but cases had a bilateral FCI score of D or worse
(Ncases = 166). In the third analysis we compared mild
CHD dogs (B/C, C/B or bilateral FCI score C) with dogs
that had moderate-to-severe (at least an FCI score D or
worse for either hip) CHD (Nmild = 124, Nmoderate-to-se-
vere = 216). The summary of the results of these three
comparisons are shown in Table 3.
A genome-wide significant association was found on
chromosome 1 for the first comparison with close to 700
dogs (Fig. 4 and Table 3). The SNPs with the strongest as-
sociation (BICF2P468585 and BICF2S23248027) passed
the threshold for significance with independent tests
(Table 3). The identified locus between NOX3 and
ARID1B is the same we found for OA (Additional file 2).
For the latter two case-control analyses with smaller num-
ber of dogs, none of the associations reached genome-
wide significance. BICF2G630837405 on chromosome 9
lies within the eighth intron of apoptosis antagonizing
transcription factor (AATF) and TIGRP2P126345 located
~ 8 kb downstream from the same gene. These two SNPs
are in high LD (r2 = 0.97, Additional file 3).
A summary of the genome-wide significant loci across
CHD-related traits described above are listed in Table 4.
The frequencies of the effect and alternative alleles of
the significantly associated SNPs in cases and controls
(binary analyses) are in Additional file 4. Some SNPs
were associated with more than one trait, as expected
when the phenotypes are not independent from each
other. The heritability (h2) estimates from the polygenic
Fig. 2 Manhattan plots for the analysis of hip joint incongruity traits FHCDAE and NoA. The upper Manhattan plot represents the results from the
analysis of FHCDAE (N = 643). The blue line indicates the threshold for significance based on the number of independent tests. The lower plot
represents the GWAS results of NoA (N = 642) with the blue line indicating the threshold for significance as in the upper plot
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mixed model for the different traits varied from 36 to
64% (Additional file 5).
Discussion
CHD is a complex skeletal disorder and one of the leading
clinical concerns in veterinary medicine. CHD is categoric-
ally scored into five classes in screening programs of the
FCI member countries but the phenotype manifests many
sub-traits, which may eventually result in painful OA. The
development of OA itself is a complex process, which in-
volves alterations in many different tissues, including bone,
cartilage, synovial membrane and ligaments [27]. Given the
complexity of the disorder, it is not surprising that genetic
discoveries have also remained scarce and breakthroughs
require large and well-phenotyped study cohorts in each
breed. We report here a remarkable progress by mapping
three new loci on different chromosomes across key CHD
traits in German Shepherds. The locus on chromosome 1
associated with OA and the FCI hip score, and the loci on
chromosomes 9 and 28 associated with the trait FHCDAE,
which measures hip joint incongruity (Table 4). In addition
to the three loci with genome-wide significance, two sug-
gestive loci on chromosomes 9 and 25 were uncovered for
OA, NoA and different FCI hip score comparisons. Besides
revealing novel loci, the study indicates that the locus on
chromosome 1 associates with two binary traits: OA and
the FCI hip score with relaxed case definition (B/C, C/B, or
C or worse in both hips). Our study partially utilizes the
Fig. 3 Manhattan plots for the binary trait: OA status. The Manhattan plot represents the lambda-corrected (lambda = 1.007) P-values from the
FASTA analysis of osteoarthritis (N = 655), where the blue line shows the threshold for significance with independent tests
Table 2 Top SNPs from the GWAS on OA
Trait Chr Locus Alleles N per SNP SNP(s) P-value from FASTA, corrected with the
inflation factor lambda (λ = 1.007)
OA status (binary; osteoarthritis present or not) 1 45,382,633
46,279,297
46,268,586
45,405,601
45,161,186
45,381,667
48,007,784
48,065,207
C/A
A/G
C/A
G/A
G/C
G/A
A/G
A/G
655
650
654
652
655
655
655
655
BICF2P468585
BICF2P357728
BICF2P1037296
BICF2S23120955
BICF2S23248027
BICF2P392839
BICF2S23216908
BICF2S2305568
2.86 × 10–7
8.93 × 10–7
2.39 × 10–6
4.48 × 10–6
5.62 × 10–6
7.05 × 10–6
7.81 × 10–6
7.81 × 10–6
9 36,579,921 A/G 655 BICF2G630837240 4.69 × 10–6
25 10,301,514 A/C 652 BICF2G630468961 6.22 × 10–6
SNPs with P-values < 1.0 × 10–5 are listed. The SNPs and their corresponding P-values are in bold font if the P-value passed the threshold for genome-wide
significance (1.82 × 10–6) determined with the estimated number of independent tests from SimpleM (see methods). N refers to the number dogs in analysis after
exclusion of dogs by FASTA because they lack either the phenotype or a covariate. Covariates for the OA status: age at radiographing, genetic cluster, genotyping
batch and birth month. See also Additional file 1
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study from Mikkola et al. (2019) [28] and as such cannot be
regarded as an independent replication study.
The locus on chromosome 1 lies in a long intergenic re-
gion between NOX3 and ARID1B (Table 5) Neither of the
genes nor the intergenic region is known for functions that
could explain their role in the development of CHD or OA.
However, the likely significance of this locus for CHD is
highlighted by the fact that our previously observed sug-
gestive association [28] was strengthened by over ten times
with a larger sample size. The association of the NOX3-
ARID1B locus to OA was 2.5 times as strong as to the FCI
hip score (as assessed by the ratio of the P-values). The
latter is an aggregate phenotype and visible signs of OA (or
the lack of them) are part of its evaluation. Therefore, it is
not surprising to observe overlapping results.
NOX3 is a member of NADPH oxidases and an interest-
ing candidate for articular cartilage degradation. NADPH
oxidase participates in the generation of hydrogen perox-
ide, which is used by myeloperoxidase as a substrate to
produce a highly reactive hypochlorous acid, and in some
circumstances chlorine gas [29, 30]. These two reactive
molecules oxidize the pyridinoline cross-links of articular
cartilage and initiate its degradation [29, 30]. The SNP
BICF2P468585 with the strongest association is ~ 196 kb
upstream from NOX3, but BICF2S23248027 (also known
as rs21911799) is located in the intron between NOX3
exons 9 and 10 (Tables 4 and 5). Moreover, NOX3 is
mainly expressed in the inner ear and fetal tissues [31],
thus, the role of NOX3 in synovial tissue inflammation re-
mains uncertain. Yet, among other protein-protein inter-
actions, a STRING [32] database search (Additional file 6)
suggested possible interplay between NOX3 and matrix
metalloproteinases 2 and 9 – two matrix degrading en-
zymes implicated in CHD and OA [33–35]. We have pre-
viously discussed [28] that there is some evidence of the
possible interplay between NOX3 and TRIO (trio Rho
guanine nucleotide exchange factor), another candidate
gene for CHD [16]. The product of T-cell lymphoma inva-
sion and metastasis 2 (TIAM2) further upstream (Table 5)
modulates the activity of Rho-like proteins [36]. ARID1B,
on the other hand, participates in transcriptional activa-
tion and repression through chromatin remodeling [37].
Interestingly, ARID1B is associated with joint laxity via a
multisystemic Coffin-Siris syndrome (CSS); CSS is caused
by ARID1B variants and 66% of the CSS patients exhibit
joint laxity [38, 39].
Previous studies have suggested seven different loci for
OA, none of them overlapping our loci. A multi-breed
study by Zhou et al. (2010) [5] suggested two loci on canine
chromosomes 17 and 37 for OA. Another quantitative trait
locus (QTL) study in a crossbreed experiment reported
putative QTLs on chromosomes 5, 18, 23 and 31 [6].
Chromosome 3 has also been suggested to harbor a QTL
that regulates cranial and caudal acetabular osteophyte for-
mation in Portuguese Water Dogs [40]. Discrepancy to our
results may result from the genetic heterogeneity in differ-
ent study populations, differences in analysis methods or
phenotyping approaches in evaluating OA.
A locus in chromosome 9 near NOG associated with
the incongruity trait FHCDAE (Tables 4 and 5). The as-
sociation of the loci with NoA were weaker than with
FHCDAE. This is not surprising as NoA suffers from
high inter-observer variability [25, 26], which was also
noted in our study. Similar bias was not seen for
FHCDAE (Additional file 1). We previously found pro-
tective regulatory variants upstream NOG, and demon-
strated the inverse correlation of their in vitro enhancer
activity with healthy hips in German Shepherds [28].
The association of this locus with FHCDAE (as assessed
by the ratio of the P-values) was ~ 24 times as strong as
what we observed for the FCI hip score [28]. The puta-
tive contribution of NOG to FHCDAE remains elusive
but may offer some leads to reduced joint congruity. De-
creased noggin activity could possibly strengthen the ac-
etabular bone via bone morphogenic protein (BMP)
signaling and help the repair of microfractures and other
damage caused by mechanical wear in growing dogs.
Interestingly, delayed ossification of the femoral head
Table 3 Top SNPs from the GWAS on different case-control analyses of the FCI hip score
Trait Chr Locus Alleles N per SNP SNP(s) P-value from FASTA, corrected with the
inflation factor lambda (λ = 1.010–1.024)
1st case-control analysis (normal hips
or mild-to-severe CHD; FCI scores)
1 45,382,633
45,161,186
46,279,297
46,268,586
C/A
G/C
A/G
C/A
693
693
689
692
BICF2P468585
BICF2S23248027
BICF2P357728
BICF2P1037296
7.03 × 10–7
1.30 × 10–6
2.52 × 10–6
9.51 × 10–6
2nd case-control analysis (normal hips
or moderate-to-severe CHD; FCI scores)
9 36,837,067
36,886,621
G/A
A/G
520
517
BICF2G630837405
TIGRP2P126345
4.96 × 10–6
7.75 × 10–6
3rd case-control analysis (mild CHD
or moderate-to-severe CHD; FCI scores)
9 36,837,067
36,886,621
G/A
A/G
340
338
BICF2G630837405
TIGRP2P126345
4.12 × 10–6
7.48 × 10–6
SNPs with P-values < 1.0 × 10–5 are listed. The SNPs and their corresponding P-values are in bold font if the P-value passed the threshold for genome-wide
significance (1.82 × 10–6) determined with the estimated number of independent tests from SimpleM (see methods). N refers to the number dogs in analysis after
exclusion of dogs by FASTA because they lack either the phenotype or a covariate. Covariates for the 1st analysis: age at radiographing and genotyping batch.
Covariates for the 2nd analysis: age at radiographing, genetic cluster, genotyping batch and birth month. Covariates for the 3rd analysis: genetic cluster,
genotyping batch and birth month. See also Additional file 1
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has been associated with CHD in later life [41, 42].
NOG is a crucial gene for many developmental pro-
cesses, such as neural tube fusion, joint formation and
skeletal development [43, 44]. In humans, dominant
NOG mutations cause some congenital disorders with
abnormal joints [45], and knocking out murine Nog
leads to a state where the mice lack most of the joints
in the limbs [46]. On the other hand, overexpression of
murine Nog results in osteopenia, bone fractures and
decreased bone formation, when the function of osteo-
blasts becomes defective [47]. A recent study by Gha-
dakzadeh et al. (2018) [48] showed that knocking-down
Nog in rats with small interfering RNA leads to down-
regulation of Nog and increases both BMP-mediated
differentiation of osteoblasts and the mineralization
process of extracellular matrix.
Fig. 4 Manhattan plots for the case-control analyses of controls and mild to severe cases. The upmost Manhattan plot represents the case-
control analysis, where controls were dogs with an FCI score A/A and cases were dogs with an FCI score B/C, C/B, or C or worse on both hips
(N = 693). The second Manhattan plot represents the case-control analysis, where cases were dogs with an FCI score D or worse on both hips
(N = 520), and the lowest Manhattan plot is the comparison between mild cases (B/C, C/B, C/C) to moderate-to-severe cases (D or worse on both
hips) (N = 340). In each plot, the blue line shows the threshold for significance with independent tests
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The third locus with genome-wide significance in-
volved also FHCDAE and resided on chromosome 28
(Tables 4 and 5). This region contains CACUL1, a cell-
cycle associated gene [49], and NANOS1 that upregu-
lates MMP14 a.k.a. membrane type 1-matrix metallopro-
teinase (MT1-MMP) thus promoting epithelial tumor
cell invasion [50]. MT1-MMP is a powerful collagenoly-
tic element [51, 52] and Miller et al. (2009) have demon-
strated the role of MT1-MMP in human rheumatoid
arthritis with synovial invasion via collagenolysis [53].
The possible role of the NANOS1 – MMP14 interplay
needs to be targeted in tissues relevant to CHD.
Intriguingly, chromosome 28 has been previously asso-
ciated with NoA in two studies of which one included
also German Shepherds [13, 54]. Although chromosome
28 did not associate with NoA in our study, the reported
NoA locus is ~ 5.2 Mb upstream from our FHCDAE
locus (Table 1). Because FHCDAE and NoA are strongly
related traits (Pearsons’s r = − 0.94, Fig. 1), additional
studies across breeds are warranted to find out whether
the two loci on chromosome 28 are related or independ-
ent, and if they possess variants contributing to CHD.
We also observed some loci showing weaker associa-
tions with NoA and OA on chromosomes 9 and 25 (Ta-
bles 1 and 2), and with FCI hip score on chromosome 9
(Table 3). These loci included relevant candidate genes
LHX1, AATF (both on chromosome 9) and SLC7A1
(chromosome 25) (Additional file 2). LHX1 could be a
candidate for OA as it has been shown to be differen-
tially methylated in OA [55] and is one of the most sig-
nificantly up-regulated genes in this disorder [56]. SNPs
near LHX1 demonstrated also a suggestive association
with CHD (quantified as the FCI hip score) in our
previous study [28]. AATF is located close to LHX1 but
its role in CHD remains uncertain. Both LHX1 and
AATF have been associated with the levels of macro-
phage inflammatory protein 1b (MIP-1b) [57, 58]. MIP-
1b is a cytokine increased in the synovial fluid in OA
and may play a role in the ingression of monocytes into
osteoarthritic joints [59]. The canine gene encoding
MIP-1b (C-C motif for chemokine ligand 4, CCL4) is lo-
cated on chromosome 9, ~ 795 kb away from
TIGRP2P126345 and ~ 803 kb from AATF (Tables 1 and
3). SLC7A1 is a high affinity cationic amino acid trans-
porter that belongs to the solute carrier family 7 [60]. It
participates in the transportation of cationic amino acids
arginine, lysine and ornithine across the plasma mem-
brane [60]. L-arginine and its methylated forms could
impact OA via the nitric oxide pathway [61].
Considering the clinical complexity of CHD, it is not
surprising that we have successfully mapped several loci,
which contain candidate genes that are involved in dif-
ferent biological pathways. Identification of these path-
ways is an important step in understanding the
pathophysiology of CHD. Some of the genes in these
networks may have no direct function on the disorder
but have a circuitous effect through other genes [62]. As
demonstrated here and previously by Sánchez-Molano
et al. (2014) [7], the complexity and polygenicity of traits
such as CHD required large sample sizes for significant
associations. Sánchez-Molano et al. (2014) [7] had a co-
hort of 1500 Labrador Retrievers, and observed two
genome-wide and multiple chromosome-wide significant
QTLs explaining maximum 23% of the genetic variance
in the analyzed traits. It is possible that larger cohorts
might reveal additional loci with smaller effects.
Table 4 Summary of the genome-wide significant SNPs for different CHD-related traits
Trait Chr Locus Alleles N per SNP SNP(s) P-value from FASTA, corrected
with the inflation factor lambda
FHCDAE 9 31,477,907 G/A 642 BICF2G630834826 1.57 × 10–6
28 29,111,565 A/C 627 BICF2P1046032 1.62 × 10–6
OA status (binary;osteoarthritis present or not) 1 45,382,633
46,279,297
C/A
A/G
655
650
BICF2P468585
BICF2P357728
2.86 × 10–7
8.93 × 10–7
Case-control analysis (normal hips or
mild-to-severe CHD; FCI scores)
1 45,382,633
45,161,186
C/A
G/C
693
693
BICF2P468585
BICF2S23248027
7.03 × 10–7
1.30 × 10–6
The threshold for genome-wide significance was 1.82 × 10–6 (independent tests correction). The candidate genes in the immediate vicinity (± 200 kb) of the SNPs
demonstrating genome-wide significance are in Table 5. All genes within ±1 Mb from the associated loci for all traits, for which P-value was < 1.0 × 10–5 are in
Additional file 2
Table 5 Candidate genes near SNPs showing genome-wide significant association with CHD-related phenotypes
Chr Locus derived from the top SNP coordinates ± 200 kb Gene(s) OA FHCDAE FCI score A vs. FCI score C to E
1 44,961,186–46,479,297 TIAM2, CLDN20, TFB1M, NOX3, ARID1B x x
9 31,187,114–31,677,907 NOG, C9H17orf67, DGKE x
28 28,911,565–29,322,985 PRLHR, CACUL1, NANOS1, EIF3A x
Total number of significant loci for the trait 1 2 1
Bold font indicates the gene(s) closest to the associated SNP. The trait associations are marked with x
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Besides sample size, accurate and reliable phenotyping
is another essential factor when studying complex traits.
This is particularly important when the trait comprises
of many interconnected sub-traits that explain only
small parts of the total variation. As long as the assess-
ment of CHD relies on the FCI scoring, it is crucial to
have standardized high-quality radiographs and a min-
imal number of people assessing them to reduce inter-
observer bias [26]. More reliable indices of joint laxity
such as the distraction or laxity index [25], could facili-
tate the discovery of genetic findings by removing some
confounding factors affecting NoA and FHCDAE, as
some laxity remains undiscovered in the extended view
radiographs.
Conclusions
In conclusion, we have performed a successful association
study with a large cohort of accurately and robustly phe-
notyped German Shepherds and describe three loci with
genome-wide significance and two suggestive loci for
CHD-related traits. The candidate genes include NOX3
and ARID1B on chromosome 1, NOG on chromosome 9,
and NANOS1 on chromosome 28. Future studies will
focus on ascertaining their role in CHD by resequencing
the candidate region for putative risk variants.
Methods
Dogs
We acquired the data for our study from the Finnish Ken-
nel Club. Before quality control we had a total of 775 sam-
ples of German Shepherds and of these 356 were controls,
322 were cases with both hip joints scored C or worse and
97 were of intermediate phenotypes with at least one hip
joint scored as B. Majority of the dogs had either the same
FCI score bilaterally or had maximum one score grade dif-
ference between the right and the left hip; three dogs had
more than one grade difference (they had been scored A/
C, C/A and B/D). The average age at radiographing was
1.55 years ranging from 1.01 to 5.83 years with a standard
deviation of 0.63 years. 435 of the dogs were female and
340 were male. We collected at least one blood sample
from all the dogs with ethylenediaminetetraacetic acid
(EDTA) as an anticoagulant.
Phenotypes
The FCI-standardized ventrodorsal extended hip radio-
graphs were taken by different veterinarians, but the hip
scoring was done by two specialized veterinarians at the
FKC. Therefore, inter-observer bias was reduced in this
data set [26]. All of the hip scores for these dogs are
available in the FKC database [63]. We had at least a
CHD score for all the dogs. We used the official FCI hip
scores to divide the dogs into two different case-control
groups: the first group with a relaxed case definition,
where the cases had an FCI score B/C (left/right hip), C/
B, or C/C or worse, and the second group with a strin-
gent case definition, where the cases had an FCI score D
or worse on both hips.
Two veterinarians in our group carefully evaluated the
acquired radiographs for more specific hip phenotypes.
These phenotypes were: findings suggestive on osteoarth-
ritis (in four categories from 0 = no signs to 3 = severe
signs), NoA (in degrees), and FHCDAE (in millimeters).
The phenotyping process was carried out as follows: One
veterinarian (evaluator 1 in the phenotype file doi: https://
doi.org/10.6084/m9.figshare.10096595) assessed all the ra-
diographs for the study cohort that was used in our previ-
ous study [28]. However, another veterinarian (evaluator 2
in the phenotype file (doi: https://doi.org/10.6084/m9.fig-
share.10096595) in our group evaluated the radiographs of
the dogs that were genotyped during the current study. A
small subset of randomly chosen radiographs, which the
evaluator 1 had previously assessed were re-assessed by
the evaluator 2 to check their consistency. In case there
were any inconsistencies, the re-assessed phenotype was
used in the analysis.
NoA varied between 70 and 108 degrees in our cohort
(Table 6); the smaller the value is, the worse is the incon-
gruity of the joint. Generally dogs with an FCI hip score A
have NoA of 105 degrees or higher [64]. Significant inter-
observer variation for NoA was seen in our data (P =
0.028, Additional file 1). We handled this in our GWAS
by using the evaluator as a covariate. FHCDAE was mea-
sured as millimeters (mm) and in our data this trait
ranged between − 4 and 15mm (Table 6). The smaller the
value is, the deeper the femoral head sits into the acetabu-
lum in relation to the dorsal acetabular edge. OA was di-
vided into four categories (the quantities for each category
here are before quality control): no signs of arthritis (0,
N = 498), some mild changes affiliated with OA (1, N =
57, minor osteophytes on the femoral neck and/or at the
craniolateral acetabular edge), moderate changes (2, N =
74, larger osteophytes, also at the dorsal acetabular edge),
or severe osteoarthritis (3, N = 33, massive osteophytes of
the femoral neck and surrounding the acetabular edge).
However, radiographs are relatively insensitive in detect-
ing early osteoarthritic changes [65]. Therefore, the
current study is unlikely to detect any associations with
loci affecting exclusively the early stages of OA.
DNA preparation and genotyping
The original EDTA preserved blood samples for this study
are stored at the Dog DNA bank at the University of
Helsinki. The DNA was extracted from these samples with a
Chemagic Magnetic Separation Module I with a standard
protocol by Chemagen (Chemagen Biopolymer-Technologie
AG, Baeswieler, Germany). Thereafter the DNA samples
were genotyped at Geneseek (Lincoln, NE, US) with a high
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density 173 K canine SNP array from Illumina (San Diego,
CA, US). Genotyping of the samples was done in multiple
batches.
Population structure
We used information from a genomic relationship
matrix built from the SNP data to divide our highly
stratified German Shepherd population into three sub-
populations (Additional file 7). For the clustering we
used an R [66] package “mclust” [67] that utilizes covari-
ance parametrization. The selection of appropriate num-
ber of clusters was executed with Bayesian information
criterion. We then created a covariate vector from the
clustering data where every individual belonged to one
of the clusters. This way we could use the clustering ef-
fect in our model to account for any differences in dis-
ease association between the genetic clusters.
Quality control (QC)
We used PLINK [68] to merge the original three geno-
type sets from different genotyping batches. A prelimin-
ary QC was done on all of the genotyping batches before
merging, with the following thresholds: call rate per
sample 0.10, call rate per SNP 0.05, minor allele fre-
quency 0.05, P-value cut-off for deviation from Hardy-
Weinberg equilibrium (HWE) 0.00001 (from controls
only). After these quality controls and data merging a
total of 100,435 SNPs and 775 samples were transferred
from PLINK to R. The final QC was done in R with
GenABEL [69], and the thresholds were: minor allele
frequency = 0.05, per sample call rate = 0.85 and per SNP
call rate = 0.95, and again a P-value cut-off level <
0.00001 to test for deviations from HWE. After the final
QC we had 89,251 autosomal SNPs and 769 samples to
use in our association analysis. However, the final
number of dogs per analysis varied between 338 and 693
as FASTA dropped individual dogs from analyses if they
missed a phenotype or a covariate. CanFam3.1 was used
as the position map for our SNPs [70]. After the GWAS
the genotype call quality of the top SNPs was checked to
exclude associations due to calling errors.
Genome-wide association analysis (GWAS)
We performed a GWAS by using polygenic mixed
models in GenABEL, with functions “polygenic” and
“mmscore” (FASTA: Score test for association in related
people) [71]. The appropriate covariates were estimated
with fitting linear regression models with the R function
“lm” from the stats-package [72] for all non-binary traits.
The binary traits were analyzed with fitting generalized
linear models with the R function “glm” [73]. The fol-
lowing covariates were tested: sex, age at radiographing,
genetic cluster of the dog, genotyping batch, birth
month, and evaluator, in other words the veterinarian
who evaluated the radiographs (tested for traits NoA,
FHCDAE and OA). The appropriate covariates which
had a significant effect (P-value < 0.05) for each
dependent trait are in Table 7 (See also Additional file
1). The inflation factor lambda for the various models
are indicated in the Tables 1-3. The corresponding Q-Q
plots are in the Additional file 8.
The r2 values for the top SNPs were estimated in R
with “r2fast” function [74] from GenABEL-package.
Bonferroni correction can be seen as a too stringent
method to correct for multiple testing as it expects
independency between the tests, which is untrue in
many association studies because of LD between
markers [75]. This is especially important to note in
canine studies, as the structure of the canine genome
is unique with strong LD due to the history of inten-
sive selection [13]. Therefore, we used the number of
independent tests to determine the threshold for sig-
nificance. We estimated the effective number of inde-
pendent tests to be 27,456 using simpleM, which uses
dimension reduction models for filtering the correla-
tions between the analyzed SNPs [76]. Based on this,
the threshold for significance 1.82 × 10–6 (0.05/27456)
is applied for P-values in this study.
Table 6 Median, interquartile range and minimum and
maximum values for the analyzed traits
Trait Median Interquartile
range
25th percentile:
75th percentile
Min – Max
NoA (degrees) 102 15 90: 105 70–108
FHCDAE (mm) 0 7 −2: 5 −4 – 15
OA (category) 0 nr nr 0–3
nr = not relevant
Table 7 Covariates for different traits
Trait Covariates chosen with lm or glm function in R
OA status (binary; osteoarthritis present or not) Age at radiographing, genotyping batch, genetic cluster and birth month
FHCDAE Age at radiographing, genetic cluster, genotyping batch
NoA Age at radiographing, genetic cluster, genotyping batch, evaluator
Cases vs. controls (FCI score categories A vs. C-E) Age at radiographing and genotyping batch
Cases vs. controls (FCI score categories A vs D-E) Age at radiographing, genetic cluster, genotyping batch and birth month
Cases vs. controls (FCI score categories C vs D-E) Genetic cluster, genotyping batch and birth month
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